Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia

Soun Khountham; Polina Shindiapina; Xiaokui Mo; Curtis Lachowiez; Tracy Wiczer; Luay Mousa; Kerry A. Rogers; Leslie A. Andritsos; Jennifer A. Woyach; John C. Byrd; Stephen E. Spurgeon; Farrukh T. Awan

doi:10.1080/10428194.2020.1838508

Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia

Soun Khountham, Polina Shindiapina, Xiaokui Mo, Curtis Lachowiez, Tracy Wiczer, Luay Mousa, Kerry A. Rogers, Leslie A. Andritsos, Jennifer A. Woyach, John C. Byrd, Stephen E. Spurgeon, Farrukh T. Awan

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	716-721
Number of pages	6
Journal	Leukemia and Lymphoma
Volume	62
Issue number	3
DOIs	https://doi.org/10.1080/10428194.2020.1838508
State	Published - 2021

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2020.1838508

Cite this

Khountham, S., Shindiapina, P., Mo, X., Lachowiez, C., Wiczer, T., Mousa, L., Rogers, K. A., Andritsos, L. A., Woyach, J. A., Byrd, J. C., Spurgeon, S. E., & Awan, F. T. (2021). Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 62(3), 716-721. https://doi.org/10.1080/10428194.2020.1838508

@article{7b8b96d2fdf54b2b9925e60da66646d5,

title = "Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia",

author = "Soun Khountham and Polina Shindiapina and Xiaokui Mo and Curtis Lachowiez and Tracy Wiczer and Luay Mousa and Rogers, {Kerry A.} and Andritsos, {Leslie A.} and Woyach, {Jennifer A.} and Byrd, {John C.} and Spurgeon, {Stephen E.} and Awan, {Farrukh T.}",

note = "Funding Information: FTA has served as a consultant for Abbvie, AstraZeneca, Acerta Pharma, Celgene, Blueprint Medicine, Gilead, Genentech, Janssen, Sunesis, Dava Oncology, Kite Pharma, Karyopharm, Verastem, MEI Pharma, Incyte. JCB is a consultant for AstraZeneca, Genentech, Acerta, and Pharmacyclics. KAR received research funding from Genentech, AbbVie, and Janssen, has consulted for Acerta Pharma, and received travel funding from AstraZeneca. LAA has served as a consultant for AstraZeneca. JAW has consulted for Pharmacyclics and Janssen and receives research funding from Pharmacyclics, Janssen, Morphosys, Karyoparm, Loxo, Abbvie, and Verastem. SES has received research funding from Acerta Pharma, Gilead Sciences Inc., Janssen, Genentech, AstraZeneca, and Bristol Myers Squibb and has provided consulting services to Gilead Sciences, Janssen, Portola Pharmaceuticals and Pharmacyclics Inc.",

year = "2021",

doi = "10.1080/10428194.2020.1838508",

language = "English (US)",

volume = "62",

pages = "716--721",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia

AU - Khountham, Soun

AU - Shindiapina, Polina

AU - Mo, Xiaokui

AU - Lachowiez, Curtis

AU - Wiczer, Tracy

AU - Mousa, Luay

AU - Rogers, Kerry A.

AU - Andritsos, Leslie A.

AU - Woyach, Jennifer A.

AU - Byrd, John C.

AU - Spurgeon, Stephen E.

AU - Awan, Farrukh T.

N1 - Funding Information: FTA has served as a consultant for Abbvie, AstraZeneca, Acerta Pharma, Celgene, Blueprint Medicine, Gilead, Genentech, Janssen, Sunesis, Dava Oncology, Kite Pharma, Karyopharm, Verastem, MEI Pharma, Incyte. JCB is a consultant for AstraZeneca, Genentech, Acerta, and Pharmacyclics. KAR received research funding from Genentech, AbbVie, and Janssen, has consulted for Acerta Pharma, and received travel funding from AstraZeneca. LAA has served as a consultant for AstraZeneca. JAW has consulted for Pharmacyclics and Janssen and receives research funding from Pharmacyclics, Janssen, Morphosys, Karyoparm, Loxo, Abbvie, and Verastem. SES has received research funding from Acerta Pharma, Gilead Sciences Inc., Janssen, Genentech, AstraZeneca, and Bristol Myers Squibb and has provided consulting services to Gilead Sciences, Janssen, Portola Pharmaceuticals and Pharmacyclics Inc.

PY - 2021

Y1 - 2021

UR - http://www.scopus.com/inward/record.url?scp=85096314635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096314635&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1838508

DO - 10.1080/10428194.2020.1838508

M3 - Article

C2 - 33210562

AN - SCOPUS:85096314635

SN - 1042-8194

VL - 62

SP - 716

EP - 721

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 3

ER -

Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this